Palvella Therapeutics announces European patent covering anhydrous compositions

Palvella Therapeutics (PVLA) “announced that the European Patent Office has issued European Patent No. 3565520, which includes claims covering QTORIN(TM) 3.9% rapamycin anhydrous gel , the Company’s lead product candidate from the QTORIN(TM) platform. The patent provides protection for anhydrous topical compositions and methods of use for QTORIN(TM) rapamycin, including for the treatment of microcystic lymphatic malformations, venous malformations, and other diseases associated with dysregulation of the mammalian target of rapamycin (mTOR) pathway.”